Special Issue

New Advance in PARP Inhibitors as Anticancer Agents

Message from the Guest Editors

PARP enzyme family members have attracted increasing interest in the last decade among both scientists in the field and clinicians due to the success of PARP inhibitors in cancer therapy. PARP inhibitors were first approved by the FDA for the treatment of BRCA1/2 mutated breast and ovarian cancers, but in recent years, they have also been used in advanced prostate and pancreas cancers. Several ongoing studies are focusing on the identification of new biomarkers and the clarification of changed molecular mechanisms in the pathophysiology of different cancer types. The results of these investigations give the possibility for the development of novel, more effective, and personalized targeted therapies. This Special Issue "New Advances in PARP Inhibitors as Anticancer Agents" of *Molecules* aims at providing an updated overview of basic and preclinical knowledge on the pathophysiology and molecular profiling of different cancer types as well as on the development of innovative targeted therapeutic approaches while taking into account promises and pitfalls.

Guest Editors

Dr. Krisztina Kovacs

Department of Biochemistry and Medical Chemistry, Medical School, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary

Prof. Dr. René Csuk

Department of Organic Chemistry, Martin-Universitat Halle-Wittenberg, Halle, Germany

Deadline for manuscript submissions

closed (30 April 2022)

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/si/99105

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/journal/molecules

MDPI

About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt
Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).